Sidewinder Therapeutics Secures $137 Million in Series B Financing to Advance Bispecific ADC Programs

Leila Ahmed North America Legal Chronicle
Tagged:

Wilson Sonsini Goodrich & Rosati has advised Sidewinder Therapeutics. Sidewinder Therapeutics, a biopharmaceutical company focused on next-generation bispecific antibody-drug conjugates (ADCs) for cancer treatment, announced the…

Membership Required

You must be a member to access this content.

View Membership Levels

Already a member? Log in here
  Share:

Author: Leila Ahmed

…

Membership Required

You must be a member to access this content.

View Membership Levels

Already a member? Log in here